Our wholly-owned CDK2i Lead Program sets new standards

OFF-state inhibition of CDK2 unlocks assets with unmatched characteristics
en route to medicines that are effective, well-tolerated, and durable

  • unprecedented levels of selectivity

  • full depth of inhibition

  • prolonged target engagement

  • durable efficacy as single agents

  • Casp-3/7-mediated apoptosis

  • no rebound, no paradoxical activation, no evasive tumor response

  • far reaching therapeutic potential

    (beyond settings with amplified Cyclin E)

  • applicable to >50% of aggressive tumors

    (e.g. mut-p53, -Ras, -PI3K, cMyc-amplified settings)


Enabled by our platform and discovery engine, the Type6 approach has propelled our CDK2i lead program onto considerably de-risked best-in-class and first-in-class trajectories . . .

. . . vastly extending the traditionally accessible CDK2 indication space . . .

. . . with the ultimate goal of delivering to patients a generation of medicines that are effective, well-tolerated, and durable.